|Articles|July 5, 2018
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
Author(s)Michelle Maskaly
New Jersey is still a top pick for companies when it comes to pharma.
Advertisement
Ki-Young Sohn, chairman and CEO of Enzychem Lifesciences, explains why the company selected New Jersey as the location for their U.S. offices.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
2
Vinay Prasad Out at CBER for Second Time in Under a Year
3
Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial
4
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
5